^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCL27 (C-C Motif Chemokine Ligand 27)

    i
    Other names: CCL27, C-C Motif Chemokine Ligand 27, CC Chemokine ILC, Skinkine, CTACK, ILC, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 27, Cutaneous T-Cell Attracting Chemokine, Chemokine (C-C Motif) Ligand 27, IL-11 R-Alpha-Locus Chemokine, IL-11 Ralpha-Locus Chemokine, Small-Inducible Cytokine A27, C-C Motif Chemokine 27, SCYA27, ESkine, PESKY, CTAK, ALP, Cutaneous T-Cell-Attracting Chemokine, ESKINE
    18d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    24d
    Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets. (PubMed, Curr Issues Mol Biol)
    Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.
    Review • Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR4 (C-C Motif Chemokine Receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL21 (C-C Motif Chemokine Ligand 21) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL27 (C-C Motif Chemokine Ligand 27) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    Poteligeo (mogamulizumab-kpkc)
    1m
    Hypersensitization of peripheral immune cells from major depressive disorder patients is mildly attenuated by fluoxetine in vitro. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
    In summary, fluoxetine has highly significant immunoregulatory effects in patients with MDD and not in controls. Unfortunately, these effects only partly attenuate the immune sensitization in MDD.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL27 (C-C Motif Chemokine Ligand 27)
    |
    fluoxetine
    1m
    Comprehensive Characterization of the Immune Microenvironment of Colorectal and Gastric Signet Ring Cell Cancer. (PubMed, Cells)
    The immune microenvironments of CR-SRCC and G-SRCC are distinct from non-SRCC. Broadly, both CR-SRCC and G-SRCC are characterized by a complex immune microenvironment that features cytotoxic cells and innate immune activity that may facilitate immune evasion.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • CCL27 (C-C Motif Chemokine Ligand 27)
    4ms
    HBV Dominance Is Associated With a Distinct Inflammatory Milieu in HBV/HCV Coinfection. (PubMed, J Viral Hepat)
    Elevated HBV activity correlates with an increased expression of soluble immune mediators, particularly influencing the alteration of key signalling pathways such as JAK-STAT and the Th17/IL-17 axis. These changes have a potential role in the development of liver fibrosis.
    Journal
    |
    IL17A (Interleukin 17A) • CCL27 (C-C Motif Chemokine Ligand 27)
    5ms
    CCR10: a comprehensive review of its function, phylogeny, role in immune cell trafficking and disease pathogenesis. (PubMed, Front Immunol)
    A deeper understanding of its mechanisms and interactions could provide valuable insights into immune system regulation, disease progression and clinical relevance. This review explores CCR10's molecular structure, biological functions, and potential for therapeutic intervention.
    Review • Journal
    |
    CCL27 (C-C Motif Chemokine Ligand 27)
    6ms
    Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma. (PubMed, bioRxiv)
    Lastly, we found that the CCL27 mutants have no toxicity in the hematopoietic compartment. This work illustrates the potential of engineering natural ligand CAR-Ts beyond their wild-type sequences and underscores the translational potential of engineered CCL27 mutant CAR-Ts.
    Journal • IO biomarker
    |
    CCL27 (C-C Motif Chemokine Ligand 27)
    9ms
    A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis. (PubMed, Glob Med Genet)
    This review focuses on the pathophysiology of the SJS and TEN and presents it in light of current data on this subject. We recommend further in vivo and in vitro studies to unravel the underlying immunological mechanisms to determine appropriate intervention strategies.
    Review • Journal
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • CCL27 (C-C Motif Chemokine Ligand 27)
    9ms
    A novel calreticulin of Psoroptes ovis regulated keratinocyte function resulting in host skin barrier dysfunction: implications for involvement in the pathogenesis of psoroptic mange. (PubMed, Parasit Vectors)
    PsoCRT disrupted the physical and immune barriers of keratinocytes, leading to skin dysfunction and facilitating a microenvironment conducive to P. ovis parasitization, thereby highlighting its important role in the pathogenesis of psoroptic mange.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CALR (Calreticulin) • CCL27 (C-C Motif Chemokine Ligand 27)
    10ms
    Identification of characteristic genes in cutaneous squamous cell carcinoma based on weighted gene co-expression network analysis. (PubMed, Front Genet)
    The identification of characteristic genes for cSCC provides valuable insights into its molecular mechanisms. The correlations between these genes and immune cell infiltration suggests their potential roles in tumor immunity.
    Journal
    |
    S100A9 (S100 Calcium Binding Protein A9) • CCL27 (C-C Motif Chemokine Ligand 27) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • LRP4 (LDL Receptor Related Protein 4)
    10ms
    Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy. (PubMed, BMC Cancer)
    sCD14 is a promising prognostic biomarker for aNSCLC patients undergoing immunotherapy. Elevated plasma sCD14 levels are associated with improved PFS and a favorable immune response.
    Journal • IO biomarker
    |
    CD14 (CD14 Molecule) • CHI3L1 (Chitinase 3-like 1) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • EGF (Epidermal growth factor) • IL17A (Interleukin 17A) • CCL27 (C-C Motif Chemokine Ligand 27) • GFAP (Glial Fibrillary Acidic Protein) • NDUFA2 (NADH:Ubiquinone Oxidoreductase Subunit A2)
    10ms
    Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS. (PubMed, NEJM Evid)
    This study demonstrates the preliminary safety of "off-the-shelf", allogeneic Treg-cell therapy.
    Journal
    |
    IL2 (Interleukin 2) • CCL27 (C-C Motif Chemokine Ligand 27)